Osaka-based Takeda Pharmaceutical Company Limited and Moderna, Inc. announced today they have agreed to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax™ vaccine from Takeda to Moderna effective August 2022. However, Takeda will continue to provide distribution support under the current national vaccination campaign for Moderna COVID-19 vaccines for a transitional period.